Commentaries
Local Experience with Vismodegib
Vismodegib, una experiencia local
P. Pasquali
Departamento de Dermatología, Pius Hospital de Valls, Cambrils, Tarragona, España
Read
3843
Timeswas read the article
1749
Total PDF
2094
Total HTML
Share statistics
array:24 [ "pii" => "S1578219018303172" "issn" => "15782190" "doi" => "10.1016/j.adengl.2018.06.024" "estado" => "S300" "fechaPublicacion" => "2018-11-01" "aid" => "2019" "copyright" => "Elsevier España, S.L.U. and AEDV" "copyrightAnyo" => "2018" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Actas Dermosifiliogr. 2018;109:765-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2 "HTML" => 2 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0001731018303363" "issn" => "00017310" "doi" => "10.1016/j.ad.2018.06.008" "estado" => "S300" "fechaPublicacion" => "2018-11-01" "aid" => "2019" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Actas Dermosifiliogr. 2018;109:765-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 165 "formatos" => array:2 [ "HTML" => 97 "PDF" => 68 ] ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Comentarios Editoriales</span>" "titulo" => "Vismodegib, una experiencia local" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "765" "paginaFinal" => "766" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Local Experience with Vismodegib" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "P. Pasquali" "autores" => array:1 [ 0 => array:2 [ "nombre" => "P." "apellidos" => "Pasquali" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219018303172" "doi" => "10.1016/j.adengl.2018.06.024" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018303172?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018303363?idApp=UINPBA000044" "url" => "/00017310/0000010900000009/v1_201811020614/S0001731018303363/v1_201811020614/es/main.assets" ] ] "itemSiguiente" => array:18 [ "pii" => "S1578219018303524" "issn" => "15782190" "doi" => "10.1016/j.adengl.2018.10.001" "estado" => "S300" "fechaPublicacion" => "2018-11-01" "aid" => "2051" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Actas Dermosifiliogr. 2018;109:766" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2 "formatos" => array:2 [ "EPUB" => 1 "HTML" => 1 ] ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Commentaries</span>" "titulo" => "An Algorithm to Guide the Rational, Evidence-Based Use of Omalizumab in the Treatment of Chronic Urticaria" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "766" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Aproximación a un uso racional y reglado de omalizumab en la urticaria crónica" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "R. Ruiz-Villaverde" "autores" => array:1 [ 0 => array:2 [ "nombre" => "R." "apellidos" => "Ruiz-Villaverde" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731018303983" "doi" => "10.1016/j.ad.2018.08.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018303983?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018303524?idApp=UINPBA000044" "url" => "/15782190/0000010900000009/v1_201811020640/S1578219018303524/v1_201811020640/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S1578219018303214" "issn" => "15782190" "doi" => "10.1016/j.adengl.2018.07.025" "estado" => "S300" "fechaPublicacion" => "2018-11-01" "aid" => "2028" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Actas Dermosifiliogr. 2018;109:765" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2 "formatos" => array:2 [ "EPUB" => 1 "HTML" => 1 ] ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Commentary</span>" "titulo" => "Coding of Dermatologic Diagnoses: An Unresolved Issue" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "765" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "La codificación de diagnósticos dermatológicos. Una cuestión aún por resolver" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "I. Belinchón Romero" "autores" => array:1 [ 0 => array:2 [ "nombre" => "I." "apellidos" => "Belinchón Romero" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731018303478" "doi" => "10.1016/j.ad.2018.07.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018303478?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018303214?idApp=UINPBA000044" "url" => "/15782190/0000010900000009/v1_201811020640/S1578219018303214/v1_201811020640/en/main.assets" ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Commentaries</span>" "titulo" => "Local Experience with Vismodegib" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "765" "paginaFinal" => "766" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "P. Pasquali" "autores" => array:1 [ 0 => array:3 [ "nombre" => "P." "apellidos" => "Pasquali" "email" => array:1 [ 0 => "pasqualipaola@gmail.com" ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Departamento de Dermatología, Pius Hospital de Valls, Cambrils, Tarragona, España" "identificador" => "aff0005" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Vismodegib, una experiencia local" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Vismodegib is the first medication to be approved by the United States Food and Drug Administration and the European Medicines Agency for the treatment of locally advanced basal cell carcinoma in patients who are not candidates for surgery or radiotherapy and for the treatment of metastatic basal cell carcinoma. Therefore, this Hedgehog pathway inhibitor has generated high hopes among oncologists and dermatologists, since no alternative treatment is available for these patients, whose condition is difficult to manage and for whom no standard therapeutic approach has been established.</p><p id="par0010" class="elsevierStylePara elsevierViewall">Initial enthusiasm has been tempered by the emergence of resistance, adverse effects that are sometimes poorly tolerated, possible liver toxicity, and a questionable increased risk of developing squamous cell carcinoma. However, experience with vismodegib as a neoadjuvant approach before surgery is growing. Similarly, we now know more about pulse dosing to diminish adverse effects and combination with other Hedgehog pathway inhibitors to increase effectiveness. Knowledge of the response to this drug in the patients we treat, therefore, is now particularly valuable; hence, the importance of the publication by Bernia et al.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> in this issue of <span class="elsevierStyleSmallCaps">Actas Dermosifiliográficas.</span></p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Pasquali P. Local Experience with Vismodegib. Actas Dermosifiliogr. 2018;109:765–766.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "Reference" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:1 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Experiencia con Vismodegib en Carcinoma Basocelular avanzado en un centro oncológico" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Bernia" 1 => "B. Llombart" 2 => "C. Serra" 3 => "B. Bancalari" 4 => "E. Nagore" 5 => "C. Requena" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2018" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000010900000009/v1_201811020640/S1578219018303172/v1_201811020640/en/main.assets" "Apartado" => array:4 [ "identificador" => "66476" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Commentaries" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000010900000009/v1_201811020640/S1578219018303172/v1_201811020640/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018303172?idApp=UINPBA000044" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 9 | 8 | 17 |
| 2024 October | 69 | 32 | 101 |
| 2024 September | 53 | 24 | 77 |
| 2024 August | 74 | 60 | 134 |
| 2024 July | 61 | 26 | 87 |
| 2024 June | 66 | 34 | 100 |
| 2024 May | 49 | 23 | 72 |
| 2024 April | 62 | 35 | 97 |
| 2024 March | 47 | 26 | 73 |
| 2024 February | 36 | 28 | 64 |
| 2024 January | 33 | 34 | 67 |
| 2023 December | 43 | 10 | 53 |
| 2023 November | 47 | 24 | 71 |
| 2023 October | 42 | 19 | 61 |
| 2023 September | 32 | 31 | 63 |
| 2023 August | 26 | 15 | 41 |
| 2023 July | 33 | 31 | 64 |
| 2023 June | 36 | 23 | 59 |
| 2023 May | 40 | 23 | 63 |
| 2023 April | 36 | 20 | 56 |
| 2023 March | 38 | 17 | 55 |
| 2023 February | 31 | 23 | 54 |
| 2023 January | 44 | 31 | 75 |
| 2022 December | 29 | 39 | 68 |
| 2022 November | 20 | 25 | 45 |
| 2022 October | 27 | 14 | 41 |
| 2022 September | 22 | 27 | 49 |
| 2022 August | 24 | 33 | 57 |
| 2022 July | 21 | 42 | 63 |
| 2022 June | 21 | 38 | 59 |
| 2022 May | 30 | 35 | 65 |
| 2022 April | 38 | 37 | 75 |
| 2022 March | 49 | 37 | 86 |
| 2022 February | 35 | 29 | 64 |
| 2022 January | 33 | 32 | 65 |
| 2021 December | 32 | 50 | 82 |
| 2021 November | 41 | 47 | 88 |
| 2021 October | 38 | 54 | 92 |
| 2021 September | 30 | 38 | 68 |
| 2021 August | 31 | 35 | 66 |
| 2021 July | 28 | 35 | 63 |
| 2021 June | 23 | 32 | 55 |
| 2021 May | 35 | 50 | 85 |
| 2021 April | 82 | 67 | 149 |
| 2021 March | 51 | 38 | 89 |
| 2021 February | 43 | 38 | 81 |
| 2021 January | 33 | 41 | 74 |
| 2020 December | 41 | 35 | 76 |
| 2020 November | 34 | 41 | 75 |
| 2020 October | 30 | 20 | 50 |
| 2020 September | 40 | 22 | 62 |
| 2020 August | 21 | 28 | 49 |
| 2020 July | 15 | 25 | 40 |
| 2020 June | 31 | 33 | 64 |
| 2020 May | 21 | 12 | 33 |
| 2020 April | 16 | 13 | 29 |
| 2020 March | 19 | 10 | 29 |
| 2020 February | 1 | 0 | 1 |
| 2019 April | 1 | 0 | 1 |
| 2018 November | 1 | 0 | 1 |
Show all
